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ABSTRACT: E3 ubiquitin ligases are attractive targets in the ubiquitin−proteasome system, however, the development of small-
molecule ligands has been rewarded with limited success. The von Hippel−Lindau protein (pVHL) is the substrate recognition
subunit of the VHL E3 ligase that targets HIF-1α for degradation. We recently reported inhibitors of the pVHL:HIF-1α
interaction, however they exhibited moderate potency. Herein, we report the design and optimization, guided by X-ray crystal
structures, of a ligand series with nanomolar binding affinities.
■ INTRODUCTION
During normal cellular homeostasis, proteins are constantly
synthesized and destroyed. The most common degradation
pathway for proteins is the ubiquitin−proteasome system (UPS),
a highly regulated signaling cascade that is responsible for the
controlled degradation of a large number of proteins upon their
polyubiquitination and ultimately hydrolysis by the proteasome.1
Dysregulation of this pathway is associated with a large number
of diseases, including cancer, neurodegenerative disorders,
diabetes, and inflammation.2,3
The therapeutic potential of intervention in the UPS has been
demonstrated by the development of proteasome inhibitors such
as peptidic boronic acid bortezomid and the epoxyketone
carfilzomib for the treatment of relapsed and/or refractory
multiple myeloma and mantle cell lymphoma.4−6 Despite these
early successes demonstrating chemical validation of the UPS as a
drug target, proteasome inhibitors have several limitations
including offering no selectivity for the large number of proteins
being targeted.
Key to protein degradation by the UPS is the recruitment of
the substrate protein by an E3 ubiquitin ligase.7 Ubiquitin ligases
confer substrate specificity for ubiquitination and could provide
more attractive targets for therapeutic intervention than current
proteasome inhibitors, making this unconventional enzyme class
most appealing for drug discovery efforts. To date, however, the
development of small molecules against E3 ligases has been
rewarded with limited success, in part because modulating their
activity and regulation requires the targeting of protein−protein
interactions (PPIs).8,9
One E3 ubiquitin ligase with important biological relevance
where some success has recently been made is the von Hippel−
Lindau protein (pVHL) Cullin RING ligase. The primary
substrate of pVHL is the hypoxia inducible factor 1α (HIF-1α), a
transcription factor that regulates over 2% of human genes,10
particularly those related to oxygen sensing and the hypoxic
response.11
Under normal oxygen levels, HIF-1α is constitutively
expressed and targeted for proteasomal degradation upon
hydroxylation by prolyl hydroxylases domain (PHD) enzymes
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at Pro402 and Pro564 within its N-terminal oxygen-degradation
domain (NODD) and C-terminal oxygen-degradation domain
(CODD), respectively, leading to specific recruitment by pVHL
and subsequent pVHL-mediated polyubiquination (Figure
1A).12 Small-molecule inhibition of this pathway would be
expected to mimic the physiological response to low oxygen
levels by increasing the expression of genes involved with the
hypoxic response.13 To this end, small-molecule PHD inhibitors
are already under examination in clinical trials for the treatment
of chronic anemia associated with chronic kidney disease and
cancer chemotherapy. Three PHDs isozymes are known (PHD1,
PHD2, and PHD3) with different substrate specificities and
cellular and tissular localization. Therefore, isoform selectivity
would be desired to avoid unwanted side effects such as
hematopoiesis or vasculogenesis. Unfortunately, none of the
current clinical compounds show sufficient PHD isozyme
selectivity.14
The development of a potent inhibitor of the pVHL:HIF-1α
interaction provides an alternative approach to PHD inhibitors
by allowing chemical intervention in the HIF pathway down-
stream of the PHD enzymes (Figure 1A). Such an approach may
avoid the HIF-independent off-target effects observed with PHD
inhibitors, thus providing a new class of lead compounds against
chronic anemia as well as acute ischemic disorders where rapid
revascularization driven by HIF-1α has proven to be beneficial.15
To validate the target chemically and to establish the
functional and biological consequences of modulating pVHL
activity, small molecules would have to bind to pVHL with
sufficient potency as to be able to compete with HIF-1α inside
the cell. Recently, a series of ligands were reported by us and
collaborators as small-molecule inhibitors of the pVHL:HIF-1α
interaction.16−19 The ligands were designed using the structure
of bound HIF-1α peptide as a starting point and growing around
the key hydroxyproline (Hyp) group to fill the left-hand side
(LHS) and right-hand side (RHS) of the PPI surface (Figure
1B,C). These molecules bound to pVHLwith moderate potency,
the best only in the single-digit micromolar range, and exhibited
very low lipophilicity due to the high hydrophilic nature of the
Hyp core scaffold. Herein, following a metrics-, structure-, and
isothermal titration calorimetry (ITC)-guided design strategy,
we describe how we have optimized the pVHL:HIF-1α inhibitor
ligand series by improving binding affinity and lipophilicity, both
being essential considerations for designing effective and cell-
active chemical probes.20
■ RESULTS AND DISCUSSION
In a previous fragment-based design study using group efficiency
(GE) and group lipophilicity efficiency (GLE), we observed that
a t-butyl group exhibits highest GE values among the groups
tested at LHS.17 Further, we showed that the LHS subpocket
responded most favorably to a t-butyl group in terms of GLE
values among all the other PPI subpockets.17 On the basis of
these observations, and on knowledge of the importance of Hyp
in the molecular recognition, we decided to select t-butyl-Hyp as
a starting anchor ligand, with a balanced lipophilicity, for the
ligand design. Ligand 2, bearing a 4-(oxazol-5-yl) benzyl group at
the RHS as employed in 1 (Figure 1C), yielded a Kd of 22 μM by
ITC (Table 1). X-ray crystal structure of the pVHL−ElonginB−
ElonginC complex (VBC) with 2 bound (Figure 2) revealed that
the t-butyl group points upward to make hydrophobic contacts
with Phe91 and Trp88 instead of pointing toward the structural
water within the LHS pocket formed by Asn67, Arg69, and
His115, as does the 3-methylisoxazole fragment of 1 and earlier
ligands.16,17
The unexpected binding mode of the t-butyl group was
observed consistently in all four VBC protomers present in the
asymmetric unit (see Supporting Information (SI) Table 1 for X-
ray data processing and refinement and SI Figure 1 for ligands
electron densities). The Hyp-NH-4-(oxazol-5-yl)benzyl portion
of the ligand is bound as previously observed for 1, forming key
hydrogen bond contacts between the Hyp-OH and His115 and
Ser111 side chains, the ligand RHS amide and His110 backbone
carbonyl and the side chain −OH of Tyr98, and the oxazoyl ring
C-2 hydrogen and nitrogen atoms with the Pro99 backbone
carbonyl and the Arg107 side chain, respectively. Notably, we
observed a wide range of dihedral angles around the phenyl−
oxazoyl C−C bond at the RHS of ligands 1 and 2 bound to the
four liganded pVHL protomers in the crystal structures (range
24−54°). Comparison of these values with the predicted lowest-
energy conformation dihedral angle calculated for this system, 0°
(Macromodel/Jaguar from Schrödinger package,21 SI Figure 2),
suggested that the bound conformation of the biaryl at the RHS
would be energetically unfavorable, so this part of the ligand
warranted further optimization.
We next sought to investigate more conformationally
constrained 5-membered oxazoyl and thiazoyl heteroaromatic
groups and their respective 4-methyl derivatives at the para-
position of the aryl ring as binding groups at the RHS (Table 1,
ligands 3−5). The 4-methylthiazole substituted ligand 5, the
most potent ligand of this series, yielded a Kd of 3.3 μM by ITC,
with slighty better potency and ligand efficiency (LE, defined as
binding energy relative to the number of heavy atomsNHA, LE =
−AG/NHA = −RT ln Kd/NHA) than ligand 1, bearing the 3-
methylisoxazole instead of t-butyl as the LHS group (Kd = 5.3
μM, LE = 0.24, Figure 1C).16,17 In the case of both oxazole and
thiazole, methylation at position 4 of the heterocycle consistently
Figure 1. (A) Under normoxic conditions, HIF-1α is hydroxylated,
recognized by VHL-E3 ligase, ubiquitinated, and degraded by the
proteasome. (B) X-ray structure of VBC (pVHL−ElonginB−ElonginC
complex) with the HIF-1α peptide bound (pink carbons, PDB 4AJY).17
(C) Example of first-generation pVHL ligand described (ligand 1).16
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increased the binding affinity, Kds 10.2 vs 22.2 μM and 3.3 vs 7.1
μM, respectively (Table 1).
To rationalize the observed SAR and confirm also the binding
mode of the t-butyl-based ligands, X-ray crystal structures of
VBC with bound ligands 3−5 were also obtained by ligand
soaking and solved to 2.1−2.6 Å resolution (SI Figure 3).
Remarkably, the aryl−aryl dihedral angle in the ligands (3−5) in
the X-ray structures was consistently found at 38° ± 4, suggesting
that this bound conformation maximizes optimal interactions at
this end of the RHS pocket. In particular the methylthiazole of 5
binds to pVHL in the RHS of the pocket without the
introduction of any strain in the dihedral angle (calculated,
43°; observed, 43°, SI Figure 2). Taken together, our results
suggest good agreement between potency and the extent of
preorganization of ligands in their bound conformation.
We next sought to obtain a ligand bearing a thiazole five-
membered ring and methyl substitution at position 3 of the
phenyl ring. Indeed, 6 bound in a conformation where no
significant strain had to be introduced to twist the biaryl
(calculated, 42°; average-observed, 43°). Although ligand 6 has a
one-digit micromolar activity, it did not show a significant
increase in potency compared to 4.
In all crystal structures of ligands 3−6 (SI Figure 3), the t-butyl
group retains the binding mode observed for 2, reinforcing its
role as a good LHS fragment. In all of the different five-
membered rings, the hydrogen at position 2 of the heterocycle at
the RHS forms an aromatic C−H···OC hydrogen bond with
the carbonyl group of Pro99, and the nitrogen atom of the
heterocyclic ring engages the side chain of Arg107 via either a
direct or a water-mediated hydrogen bond. Importantly for this
series, the introduction of the lipophilic t-butyl group increases
the clogP of the ligands, bringing it into a more optimal range for
further optimization (Table 1).
Overlaying of the crystal structures of ligands 2−6 bound to
pVHL with that of the HIF-1α peptide revealed that the −CH2
and quaternary carbons of the t-butyl group overlap very well
with Cα and Cβ of the Ala563 residue of the HIF-1α peptide,
respectively (SI Figure 4). This observation suggested an
attractive vector to grow the compounds into the empty pocket
at the LHS that is occupied by Leu562 of the peptide by
mimicking the peptidic backbone structure. We therefore
synthesized 7 that adds an acetamido group to ligand 5, the
best binder of the previous series, by coupling a L-tert-leucine
amino acid to the Hyp-RHS core and then N-terminally
acetylating the resulting product. Gratifyingly, 7 showed a Kd
of 185 nM as determined by ITC (LE = 0.28), an almost 20-fold
increase in affinity compared to 5, affording a ligand that is even
more potent than the 10-mer model HIF-1α peptide (Kd = 200
nM, LE = 0.12). The crystal structure of 7 bound to VBC (Figure
3) confirmed the expected interaction of the carbonyl group with
the structural water at the LHS pocket, recapitulating well the
interaction observed with the HIF peptide while the amido NH
points outward toward the solvent.
Table 1. Structures, Kds, and ΔH Determined by ITC, LEs,
and Calculated log Ps23
Figure 2. Crystal structure of VBC in complex with ligand 1 (gray
carbons, PDB 3ZRC)16 and 2 (purple carbons, PDB 4W9C). pVHL is
shown as a pale-green surface and the pVHL residues forming the
binding pocket as yellow stick representations. The structural water at
the LHS is shown as red sphere.
Figure 3.Crystal structure of VBC in complex with the ligand 7 (orange
carbons, PDB 4W9H). Hydrogen bonds with the structural water (red
sphere) are shown as blue-dashed lines. pVHL is shown as a pale-green
surface and pVHL residues forming the binding pocket as yellow sticks.
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To assess the importance of the t-butyl group of 7 for the
molecular recognition, we asked whether groups with different
steric requirements and lipophilicities could substitute for it. We
therefore synthesized analogues replacing the tert-leucine moiety
of 7 with phenylglycine (8) as well as the more conformationally
constrained five-membered ring proline (9) and hydroxyproline
(10) and the six-membered ring pipecolic acid (11) to achieve
cyclizing of the side chain with the solvent-exposed amido
nitrogen. All analogues exhibited Kd values of around or below 1
μM, but weaker binding affinities when compared to 7 (Table 2),
presumably the result of unfavorable steric constraints. Ligand 11
with a more relaxed six-membered ring was the best binder
among this new series. The importance of steric constraints at
this position was confirmed by solving the X-ray crystal structure
of the hydroxyproline analogue 10 bound to VBC, which showed
that the five-membered ring twists the amide bond, resulting in a
less favorable interaction with the structural water (SI Figure 5).
An interesting feature of this structure is the formation of water-
mediated hydrogen bonds between the Hyp-OH in the LHS and
the side chain of Gln96, consistent with similar interactions
observed with previous ligands.18 This new interaction may be
reflected in the larger ΔH contribution to binding observed for
10 with respect to other ligands in the series.
Having established the t-butyl group as the best fragment for
the LHS1 pocket (from this point, we define LHS1 as the surface
bound by the t-butyl group and LHS2 as the surface where the
structural water remains in place, filled by Leu562 of the HIF-1α
peptide), we next designed and synthesized a set of ligands
growing away from the terminal acetyl group of 7, further
mimicking the structure of the bound HIF peptide at the LHS2
pocket. We therefore coupled a range ofN-acetylated natural and
unnatural L-amino acids to the LHS1 t-butyl group, including
alanine (12), leucine (13), phenylalanine (14), tert-leucine (15),
phenylglycine (16), and a cyclized phenylalanine (17) (Table 3).
When we attached a bulky alkyl chain directly to the backbone
(15, 16), a drop in potency was observed, probably due to steric
clashes with the protein. Ligand 13, mimicking the Leu562 of the
HIF-1α peptide backbone, and the alanine-substituted ligand 12
yielded nanomolar affinity to pVHL. The most potent
compound of this series was the phenylalanine-substituted
ligand (14, Kd = 290 nM, LE = 0.20). Unfortunately, the
conformationally constrained ligand 17 did not yield an increase
in the affinity.
To gain insight into the molecular determinants that modulate
the range of activities determined for the ligands of this series,
crystal structures of VBC bound to 13, 14, and 15 were solved.
The structures showed that the ligands maintain many of the
previously highlighted interactions; introduction of these new
groups at the LHS2 did not affect the binding mode of the
remaining parts of the molecules. The aliphatic alkyl chains in
Table 2. Structures,Kds andΔHDetermined by ITC, LEs, and
Calculated log Ps23
Table 3. Structures, Kds, and ΔH Determined by ITC, LEs,
and Calculated log Ps23
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ligands 13 (Figure 4A) and 15 (SI Figure 6) overlap well with the
conformation that the Leu562 has in the natural HIF-1α peptide,
however, in the case of 15, steric clashes with the Tyr112 of the
protein were observed, resulting in loss of affinity. Interestingly,
we observed significant conformational changes in the LHS2 of
the protein to accommodate the aryl phenylalanine side chain of
14 (Figure 4B). Ligand 13 makes bidentate hydrogen bonds
from the terminal acetamido with the Asn67 side chain, however,
these interactions are lost in the case of the ligand 14 due to
rearrangement of the terminal Ac-Phe portion of the ligand.
Although none of the LHS2-targeting ligands increased the
affinity toward the pVHL when compared to 7, they have
revealed new ligand binding modes and pocket flexibility at this
part of the PPI that open up opportunities to explore further
optimization of best-in-class ligand 7 within this region.
Extending ligands further at LHS2 could not only improve
affinity of current ligands but also add to the arsenal of linkable
pVHL ligands for proteolysis-targeting chimeras (PROTACs)
small-molecule approaches.22
■ CONCLUSIONS
Because of a historical paucity of conventional drug discovery
approaches to effectively target protein−protein interactions,
only a few E3 ubiquitin ligases have been successfully modulated
to date and the field is still in its infancy. We describe the
structure-based design, synthesis, and optimization of next-
generation small molecules targeting pVHL, an important E3
ligase and a potential drug target, with binding affinities in the
nanomolar range and improved lipophilicity. X-ray crystal
structures and ITC studies reveal new interactions on the left-
hand side of the pocket and elucidate the structural and
thermodynamic determinants for the improvement in binding
affinities, thus providing crucial information for future ligand
optimization campaigns. Our best ligand 7, to our knowledge the
most potent pVHL:HIF-1α inhibitor described to date, is more
potent than a model 10-mer HIF-1α peptide, providing an
excellent starting point to validate VHL as a drug target. Work is
presently ongoing in our laboratory to assess the cellular activity
and bioavailability of these ligands. Moreover, our group analysis
has proven to be a useful tool to guide the optimization of future
pVHL ligands. Our successful approach points out the
importance of a parallel structure-driven and metrics-driven
design to understand and modulate challenging PPIs, opening
new opportunities for targeting other members of the family of
E3 enzymes considered too risky for the pharmaceutical industry
until this moment.
■ EXPERIMENTAL SECTION
Chemistry. General directions are in the SI. For each ligand, a full
description of the synthetic protocols and spectroscopic analysis can be
found in the SI. All of the tested ligands (2−17) were evaluated after the
corresponding flash column chromatography purification, followed by
preparative LC-MS purification. The purity of all compounds was
analyzed by HPLC-MS (ESI) and is >95%. The synthetic procedure for
the preparation of new ligands described herein is exemplified through
the synthesis of 7 (Scheme 1).
General Method A. To a solution of amine (1 equiv) in DMF was
added the appropriate acid (1 equiv), and the solution was stirred at
room temperature. DIPEA (4 equiv) was added dropwise, and the
mixture was stirred for 5 min at room temperature. HATU (1.1 equiv)
was added, and the mixture was stirred at room temperature for another
30 min. Water was added, and the mixture was extracted with ethyl
acetate (3×). The combined organic phases were washed with brine
(×2), dried over MgSO4, and evaporated under reduced pressure to give
the corresponding crude, which was purified by flash column
chromatography purification to yield the final compound.
General Method B. The corresponding NH2 deprotected amino
acid derivate (1 equiv) was dissolved in DCM, and triethylamine (3
equiv) was added to the solution. After stirring the mixture for 10 min at
room temperature, acetic anhydride (1.5 equiv) was added and the
reaction was stirred 90 min at room temperature. The solvents were
evaporated under reduced pressure to give the corresponding crude,
which was purified by flash column chromatography to yield the final
compound.
(4-(4-Methylthiazol-5-yl)phenyl)methanamine (18). To a solution
of 4-bromobenzonitrile (1.5 g, 8.24 mmol, 1 equiv) and Pd(OAc)2 (2
mg, 0.08 mmol, 0.1 mol %) in DMAc (8 mL) were added KOAc (1.62 g,
16.5 mmol, 2 equiv) and 4-methylthiazole (1.63 g, 1.49 mL, 16.5 mmol,
2 equiv). The resulting mixture was heated to 150 °C and stirred
overnight. The mixture was diluted with water and extracted with DCM
(3×). The combined organic phases were dried over MgSO4 and
evaporated under reduced pressure to give the corresponding cyano
derivate as a beige solid (1.67 g, 7.99 mmol, 97%) that matched the
reported spectral data.17 A solution of the cyano derivate product (270
mg, 1.3 mmol, 1 equiv) in methanol (15 mL) was cooled to 0 °C. CoCl2
(282 mg, 2.2 mmol, 1.5 equiv) was added, followed by portionwise
addition of NaBH4 (274 mg, 7.2 mmol, 5 equiv). The resulting mixture
was stirred for 90 min, the reaction was quenched with water and
ammonium hydroxide, and the mixture was extracted with chloroform
Figure 4. Crystal structure of the VBC in complex with (A) ligand 13
(cyan carbons, PDB 4W9J) with boundHIF-1α peptide superposed and
(B) ligand 14 (gray carbons, PDB 4W9K). Hydrogen bonds are shown
as blue-dashed lines. pVHL is shown as a pale-green surface and the
pVHL residues forming the binding pocket as yellow sticks.
Scheme 1. Synthesis of the Ligand 7a
aConditions: (i) Pd(OAc)2, KOAc, DMAc, reflux, O/N; (ii) NaBH4,
CoCl2, MeOH, 0 °C, 90 min; (iii) Boc-Hyp-OH, DIPEA, HATU,
DMF, rt, 30 min; (iv) TFA/DCM 1:1, rt, 30 min; (v) Boc-L-tert-
leucine, DIPEA, HATU, DMF, rt, 30 min; (vi) TFA/DCM 1:1, rt, 30
min; (vii) acetic anhydride, N(Et)3, DCM, rt, 90 min.
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(6×). The combined organic phases were dried over MgSO4 and
evaporated under reduced pressure to give a dark-brown oil which was
purified by flash column chromatography to yield the product 18 as a
yellow oil (76.5 mg, 0.40 mmol, 29% (isolated)) that matched the
reported spectral data.18 MS (ESI): [M + 1] calculated 205.1; observed
188.1 (fragmentation).
(2S,4R)-tert-Butyl-4-hydroxy-2-((4-(4-methyl thiazol-5-yl)benzyl)-
carbamoyl)pyrrolidine-1-carboxylate (19). Following the general
method A, from 18 (340 mg, 1.66 mmol, 1 equiv) and Boc-Hyp-OH
(383 mg, 1.66 mmol, 1 equiv), ligand 19 was obtained as a yellow solid
(658 mg, 1.58 mmol, 95%) that matched the reported spectral data.18
MS (ESI): [M + 1] calculated 418.2; observed 418.2.
tert-Butyl((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazole-5-yl)-
benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-
carbamate (20). A solution of ligand 19 (340 mg, 0.81 mmol) in 1:1
TFA:DCM (8 mL) was stirred at room temperature for 30 min. The
mixture was evaporated under reduced pressure to give the
corresponding deprotected intermediate (TFA salt) as a brown oil
without further purification (330mg, 0.77mmol, 98%) that matched the
reported spectral data.18 Following the general method A, from the
deprotected intermediate (330 mg, 0.77 mmol, 1 equiv) and Boc-L-tert-
leucine (178mg, 0.77mmol, 1 equiv), ligand 20was obtained as a yellow
solid (400 mg, 0.75 mmol, 98%), which was used directly for the next
step. MS (ESI): [M + 1] calculated 531.3; observed 531.3.
(2S,4R)-1-((S)-2-Acetamido-3,3-dimethyl butanoyl)-4-hydroxy-N-
(4-(4-methylthiazol-5-yl) benzyl)pyrrolidine-2-carboxamide (7). A
solution of ligand 20 (257 mg, 0.48 mmol) in 1:1 TFA:DCM (5 mL)
was stirred at room temperature for 30 min. Themixture was evaporated
under reduced pressure to give the corresponding intermediate (TFA
salt), which was used directly for the next step. Following the general
method B, from the corresponding deprotected amine (TFA salt, 275
mg, 0.50 mmol, 1 equiv), ligand 7was obtained as colorless oil (65.3 mg,
0.14 mmol, 27%). 1H NMR (CDCl3, 500 MHz): δ 8.67 (s, 1H), 7.35
(dd, J = 15.0, 10.0 Hz, 4H), 4.71 (t, J = 10.0 Hz, 1H), 4.56−4.48 (m,
3H), 4.33 (dd, J = 15.0, 10.0, 1H), 4.07 (d, J = 10 Hz, 1H), 3.60 (dd, J =
10.0, 5.0 Hz, 1H), 2.60 (s, 2H), 2.50 (s, 3H), 2.14−2.10 (m, 1H), 1.98 (s,
3H), 0.93 (s, 9H). 13C NMR (CDCl3, 125 MHz): δ 172.1, 170.9, 170.8,
150.4, 148.7, 138.2, 131.8, 131.2, 129.7, 128.3, 70.2, 58.6, 57.7, 56.8,
45.7, 43.2, 36.0, 35.0, 26.5, 8.6. HRMS (ESI)m/z: [M + 1] calculated for
C24H33N4O4S: 473.2222; observed 473.2211.
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■ ABBREVIATIONS USED
CODD, C-terminal oxygen-degradation domain; GE, group
efficiency; GLE, group lipophilicity efficiency; HIF-1α, hypoxia
inducible factor 1 alpha; ITC, isothermal titration calorimetry;
LE, ligand efficiency; LHS, left-hand side; NODD, N-terminal
oxygen-degradation domain; O/N, overnight; PHD, prolyl
hydroxylase domain; PPI, protein−protein interaction; RHS,
right-hand side; SAR, structure−activity relationships; UPS,
ubiquitin−proteasome system; VBC, VHL-EloB-EloC; pVHL,
von Hippel−Lindau protein
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